Virpax Pharmaceuticals, Inc. (VRPX) Balance Sheet
VRPX balance sheet, 2024
December 31, 2024 · U.S. dollars$1.6M assets = $2.5M liabilities + −$913,760 equity
Liabilities exceed assets: shareholders’ equity is negative (−$913,760).
Both columns are drawn to the same scale: what VRPX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
VRPX financial health
Descriptive bands, not a rating. Fiscal 2024.
VRPX balance sheet trends, 2018–2024
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $61,5002018 | $1.6M2024 | +71.3%/yr | |
| Total liabilities | $1.3M2018 | $2.5M2024 | +12.0%/yr | |
| Shareholders’ equity | −$1.2M2018 | −$913,7602024 | — | |
| Cash & short-term investments | $48,3702018 | $1.5M2024 | +77.5%/yr | |
| Total debt | $500,0002018 | $1.6M2020 | +77.0%/yr | |
| Net cash (debt) | −$451,6302018 | −$1.5M2020 | −$1.1M | |
| Working capital | −$1.2M2018 | −$913,7602024 | +$278,964 | |
| Book value per share | −$0.242018 | −$0.212024 | — | |
| Current ratio | 0.052018 | 0.632024 | +0.58 | |
| Shares outstanding | 4.9M2018 | 4.3M2024 | −2.5%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
VRPX assets
VRPX liabilities and equity
VRPX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
VRPX balance sheet
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & short-term investments | $1.5M | $9.1M | $19.0M | $36.8M | $54,796 | $41,536 | $48,370 |
| Cash & equivalents | $1.5M | $9.1M | $19.0M | $36.8M | $54,796 | $41,536 | $48,370 |
| Short-term investments | $1.51B | — | — | — | — | — | — |
| Receivables | $0 | $0 | $0 | $0 | $0 | $1,388 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $3,328 | $0 |
| Other current assets | $42,557 | $486,833 | $678,365 | $2.7M | $18,273 | $467 | $13,130 |
| Total current assets | $1.6M | $9.6M | $19.7M | $39.6M | $73,069 | $46,719 | $61,500 |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $392,337 | $0 | $0 |
| Total assets | $1.6M | $9.6M | $19.7M | $39.6M | $465,406 | $46,719 | $61,500 |
| Liabilities | |||||||
| Accounts payable | $18,457 | $18 | $37,644 | $19,841 | $22,107 | $3,495 | $6,553 |
| Short-term debt | — | — | — | — | $543,990 | $1.3M | $500,000 |
| Deferred revenue | — | — | — | — | −$1.0M | −$4 | −$6,553 |
| Total current liabilities | $2.5M | $7.7M | $3.1M | $2.1M | $3.7M | $2.8M | $1.3M |
| Long-term debt | $0 | $0 | $0 | $0 | $1.0M | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $1,095 | $0 | $0 | $1.3M | $500,000 |
| Total liabilities | $2.5M | $7.7M | $3.1M | $2.1M | $4.7M | $2.8M | $1.3M |
| Shareholders' equity | |||||||
| Common stock & paid-in capital | $149 | $12 | $117 | $117 | $31 | $30 | $29 |
| Retained earnings (deficit) | −$71.6M | −$59.5M | −$44.4M | −$22.7M | −$10.6M | −$6.3M | −$3.0M |
| Accumulated other comprehensive income | $0 | $0 | $0 | $0 | — | $0 | — |
| Total shareholders' equity | −$913,760 | $1.9M | $16.6M | $37.5M | −$4.2M | −$2.7M | −$1.2M |
| Key figures | |||||||
| Total debt | — | — | — | — | $1.6M | $1.3M | $500,000 |
| Net cash (debt) | — | — | — | — | −$1.5M | −$1.2M | −$451,630 |
| Working capital | −$913,760 | $1.9M | $16.6M | $37.5M | −$3.6M | −$2.7M | −$1.2M |
| Tangible book value | −$913,760 | $1.9M | $16.6M | $37.5M | −$4.2M | −$2.7M | −$1.2M |
| Book value per share | −$0.21 | $1.65 | $14.16 | $32.00 | −$8.53 | −$5.24 | −$0.24 |
| Shares outstanding | 4.3M | 1.2M | 1.2M | 1.2M | 495K | 522K | 4.9M |
| Current ratio | 0.63 | 1.25 | 6.36 | 18.96 | 0.02 | 0.02 | 0.05 |
| Quick ratio | 0.61 | 1.19 | 6.14 | 17.65 | 0.01 | 0.02 | 0.04 |
| Equity / assets | −58.7% | 20.1% | 84.3% | 94.7% | −905.9% | −5,848.3% | −1,939.4% |
| Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $1.5M | $17,229 | $1.9M | $1.9M | $9.1M | $12.2M | $14.8M | $17.0M | $19.0M | $20.6M | $26.1M | $30.8M |
| Cash & equivalents | $1.5M | $17,229 | $1.9M | $1.9M | $9.1M | $12.2M | $14.8M | $17.0M | $19.0M | $20.6M | $26.1M | $30.8M |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $42,557 | $286,933 | $719,880 | $1.3M | $486,833 | $885,394 | $1.1M | $1.5M | $678,365 | $3.1M | $3.3M | $3.9M |
| Total current assets | $1.6M | $304,162 | $2.6M | $3.1M | $9.6M | $13.0M | $16.0M | $18.5M | $19.7M | $23.6M | $29.4M | $34.7M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $1.6M | $304,162 | $2.6M | $3.1M | $9.6M | $13.0M | $16.0M | $18.5M | $19.7M | $23.6M | $29.4M | $34.7M |
| Liabilities | ||||||||||||
| Accounts payable | — | $96,278 | $75,399 | $13,275 | $18,457 | $33,192 | $76,062 | $45,246 | $37,644 | $14,321 | $20,239 | $10,400 |
| Total current liabilities | $2.5M | $2.4M | $5.4M | $4.3M | $7.7M | $6.5M | $3.6M | $3.3M | $3.1M | $4.2M | $2.5M | $2.2M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.1M | $4.2M | $2.5M | $0 |
| Total liabilities | $2.5M | $2.4M | $5.4M | $4.3M | $7.7M | $6.5M | $3.6M | $3.3M | $3.1M | $4.2M | $2.5M | $2.2M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $149 | $49 | $28 | $12 | $12 | $117 | $117 | $117 | $117 | $117 | $117 | $117 |
| Retained earnings (deficit) | −$71.6M | −$68.2M | −$66.2M | −$62.8M | −$59.5M | −$55.0M | −$49.0M | −$45.9M | −$44.4M | −$41.4M | −$33.7M | −$27.8M |
| Accumulated other comprehensive income | — | — | — | $0 | $0 | — | — | — | $0 | — | $0 | $0 |
| Total shareholders' equity | −$913,760 | −$2.1M | −$2.8M | −$1.2M | $1.9M | $6.5M | $12.3M | $15.2M | $16.6M | $19.4M | $26.9M | $32.6M |
| Key figures | ||||||||||||
| Working capital | −$913,760 | −$2.1M | −$2.8M | −$1.2M | $1.9M | $6.5M | $12.3M | $15.2M | $16.6M | $19.4M | $26.9M | $32.6M |
| Tangible book value | −$913,760 | −$2.1M | −$2.8M | −$1.2M | $1.9M | $6.5M | $12.3M | $15.2M | $16.6M | $19.4M | $26.9M | $32.6M |
| Book value per share | −$0.21 | −$0.44 | −$1.41 | −$1.04 | $1.65 | $5.55 | $10.50 | $12.97 | $14.15 | — | — | — |
| Shares outstanding | 4.3M | 4.7M | 2.0M | 1.2M | 1.2M | 1.2M | 1.2M | 1.2M | 1.2M | — | — | — |
| Current ratio | 0.63 | 0.13 | 0.48 | 0.72 | 1.25 | 2.00 | 4.37 | 5.61 | 6.36 | 5.62 | 11.84 | 15.89 |
| Quick ratio | 0.61 | 0.01 | 0.35 | 0.43 | 1.19 | 1.86 | 4.06 | 5.16 | 6.14 | 4.89 | 10.49 | 14.08 |
| Equity / assets | −58.7% | −674.5% | −107.9% | −38.8% | 20.1% | 49.9% | 77.1% | 82.2% | 84.3% | 82.2% | 91.6% | 93.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 3, 2025); data from EODHD.
VRPX financial position
At the end of fiscal 2024 (December 31, 2024), Virpax Pharmaceuticals had total assets of $1.6 million (down 83.8% from a year earlier), total liabilities of $2.5 million and shareholders' equity of -$0.9 million. Its current ratio was 0.63.
Related: VRPX income statement, VRPX cash flow statement, VRPX key metrics. See the VRPX stock overview for the latest quote and news.
VRPX balance sheet FAQ
What are Virpax Pharmaceuticals's total assets?
Virpax Pharmaceuticals reported total assets of $1.6 million at the end of fiscal 2024 (December 31, 2024), compared with $9.6 million a year earlier.
How much cash does Virpax Pharmaceuticals have?
Virpax Pharmaceuticals held $1.5 million in cash and short-term investments at the end of fiscal 2024.
What is Virpax Pharmaceuticals's book value?
Virpax Pharmaceuticals's shareholders' equity (book value) was -$0.9 million at the end of fiscal 2024, or −$0.21 per share.
What is Virpax Pharmaceuticals's current ratio?
Virpax Pharmaceuticals had current assets of $1.6 million and current liabilities of $2.5 million, a current ratio of 0.63 (current liabilities exceed current assets).